ライフサイエンスコーパス: breast cancer case

1 median follow-up, 8.9 years; 1,905 invasive breast cancer cases).

2 at MR imaging--was similarly matched to each breast cancer case.

3 t strategies to prevent cancer metastasis in breast cancer cases.

4 clin D1 is overexpressed in about 35% of all breast cancer cases.

5 f BRCA2 account for about 10-30% of familial breast cancer cases.

6 ignificantly with Drg-1 in both prostate and breast cancer cases.

7 xifene for 4 years would have avoided 47% of breast cancer cases.

8 d 41 randomly selected, age-matched sporadic breast cancer cases.

9 and BRCA1 are responsible for most familial breast cancer cases.

10 may be associated with a large proportion of breast cancer cases.

11 aplasia and cancer was studied in a panel of breast cancer cases.

12 rm-line RAD52 alleles from 5% of early-onset breast cancer cases.

13 onic polyps, no examples were found in these breast cancer cases.

14 ions may account for approximately 5% of all breast cancer cases.

15 unt for a comparable percentage of inherited breast cancer cases.

16 er-volume surgeons with a high percentage of breast cancer cases.

17 ss that causes TP53 mutations in a subset of breast cancer cases.

18 e, facility type and location, and volume of breast cancer cases.

19 5 person-years, we identified 3,549 incident breast cancer cases.

20 ulation structure and evolution in two human breast cancer cases.

21 of them accounting for roughly one third of breast cancer cases.

22 Of the 288 breast cancer cases, 19 (6.6%) inherited disease-predisp

23 itional cases, for a total of 7,006 incident breast cancer cases (1976-2002).

24 trate these methods using a series of 25,962 breast cancer cases (1988-2004) from the West Midlands,

25 years of additional follow-up, 104 incident breast cancer cases, 20 of which appeared in women with

26 a nested case-control study of 302 women (69 breast cancer cases, 233 controls) who had been initiall

27 based study in North Carolina comprising 791 breast cancer cases (302 in African-American women and 4

28 Of 510 male breast cancer cases (456 white, 34 black), 94% underwent

29 2002) of postmenopausal Caucasian women (522 breast cancer cases, 708 controls).

30 n 4.3 million fewer cHT users, 126,000 fewer breast cancer cases, 76,000 fewer cardiovascular disease

31 at P </= 1 x 10(-5) in an additional 11 209 breast cancer cases (946 with ER-negative disease) and 1

32 d 40 to 74 years was projected to induce 125 breast cancer cases (95% CI, 88 to 178) leading to 16 de

33 tions on informal caregiving; 1,700 incident breast cancer cases accrued over follow-up to 2000.

34 ed, North Carolina case-control study of 862 breast cancer cases aged 20-74 years diagnosed during 19

35 exican women during 1992-1994 using incident breast cancer cases aged 35-74 years and frequency-match

36 Breast cancer cases aged 50-79 years (n = 5,559) and end

37 In a Swedish family with five breast cancer cases, all analyzed tumors showed distinct

38 umor tissues showed no mutation in the index breast cancer case and revealed the presence of at least

39 yped rs2735383 in 1,170 familial non-BRCA1/2 breast cancer cases and 1,077 controls using PCR-based r

40 cted 24 SNPs for further genotyping in 1,516 breast cancer cases and 1,189 noncancer controls.

41 A total of 1,434 breast cancer cases and 1,440 controls provided adequate

42 e-wide association studies, including 10,052 breast cancer cases and 12,575 controls of European ance

43 tion studies among 10,146 non-Hispanic white breast cancer cases and 12,760 controls within the Natio

44 A case-control study was conducted among 120 breast cancer cases and 120 controls.

45 ene in breast cancer risk in a study of 1193 breast cancer cases and 1310 matched controls from the S

46 meta-analysis of 11 GWAS, comprising 15,748 breast cancer cases and 18,084 controls together with 46

47 A total of 304 breast cancer cases and 186 controls aged 40-79 years we

48 A total of 293 breast cancer cases and 240 controls with at least one o

49 ted with breast cancer among 2,604 Caucasian breast cancer cases and 3,118 matched controls.

50 ide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of

51 reast cancer risk among 268 family sets (287 breast cancer cases and 350 sister controls).

52 re estimated by using data on 3,499 invasive breast cancer cases and 4,213 controls from a population

53 stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls, followed by a th

54 The authors compared 5,358 newly diagnosed breast cancer cases and 4,555 controls interviewed from

55 region around CASP8 were genotyped in 46 450 breast cancer cases and 42 600 controls of European orig

56 14q24.1 (RAD51L1), for up to 46 036 invasive breast cancer cases and 46 930 controls from 39 studies.

57 rs2735383 genotypes (r(2) > 0.999) of 47,640 breast cancer cases and 46,656 controls from the Breast

58 CYP1A1 by PCR-RFLP assays among 466 incident breast cancer cases and 466 matched controls.

59 actor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast

60 sed these to construct risk scores for 3,628 breast cancer cases and 5,190 controls from the UK2 GWAS

61 otyping these SNPs in 6,800 population-based breast cancer cases and 6,613 controls identified a simi

62 Among a subgroup of 362 breast cancer cases and 611 matched controls with plasma

63 control study in 621 postmenopausal invasive breast cancer cases and 621 matched controls in the mult

64 nested case-control study consisting of 604 breast cancer cases and 626 controls with prospectively

65 alysis of genotyping data from 8635 familial breast cancer cases and 6625 controls from different cou

66 his study was conducted among 5,356 invasive breast cancer cases and 7,129 controls comprised primari

67 This study includes 5,370 breast cancer cases and 7,480 matched controls from five

68 gnostic first-morning urine samples from 251 breast cancer cases and 727 matched controls.

69 es collected between 1996 and 1999 among 600 breast cancer cases and 786 matched controls.

70 We genotyped 733 hospital-based breast cancer cases and 839 controls for 10 haplotype-ta

71 gas chromatography mass spectrometry for 436 breast cancer cases and 852 individually matched control

72 DNA (saliva) was available for 920 breast cancer cases and 960 controls.

73 from the FGFR2 region, in 950 consecutive AJ breast cancer cases and 979 age-matched AJ controls.

74 ream of the transcription start site) in 947 breast cancer cases and 993 age frequency-matched commun

75 principal components factor analysis in 1097 breast cancer cases and an age-stratified subcohort of 3

76 Here, in a larger sample of breast cancer cases and controls (n = 1,322/n = 1,953) n

77 c markers to estimate the ancestry of Latina breast cancer cases and controls and assessed the associ

78 content of adipose tissue in postmenopausal breast cancer cases and controls from five European coun

79 SR1 gene variants (SNPs) in more than 55,000 breast cancer cases and controls from studies within the

80 as validated, compared with self-report, for breast cancer cases and controls in Utah and New Mexico.

81 ography; and the number of radiation-induced breast cancer cases and deaths associated with different

82 Breast cancer cases and estrogen receptor and progestero

83 trieved several prediagnostic mammograms for breast cancer cases and for controls frequency-matched t

84 Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours.

85 Bilateral breast cancer cases and their families are likely to pro

86 ologic information databases that identified breast cancer cases and tumor characteristics.

87 Us) and malignant epithelial samples from 18 breast cancer cases, and examined their DNA for LOH at 2

88 D-BP gene is amplified in one-third of human breast cancer cases, and the CRD-BP appears to be an onc

89 Families with three or more breast cancer cases are being used in traditional linkag

90 70% of all breast cancer cases are estrogen receptor (ER)-positive

91 A population-based series of 469 bilateral breast cancer cases ascertained through English cancer r

92 , 3.61; 95% CI, 1.11-11.7; percentage of all breast cancer cases attributable to this risk factor, 2.

93 , 5.65; 95% CI, 1.50-21.3; percentage of all breast cancer cases attributable to this risk factor, 2.

94 tion of one intragenic repetitive element in breast cancer cases compared with controls (P = 0.0017),

95 was significantly higher in triple-negative breast cancer cases compared with normal mammary tissues

96 yped in 1,482 DNA samples from a Mayo Clinic breast cancer case control study.

97 el and then evaluate their human homologs in breast cancer case-control association studies.

98 When it was applied to a sporadic breast cancer case-control data set, in the absence of a

99 variable in a logistic regression model with breast cancer case-control status as the outcome.

100 st cancer was tested in two population-based breast cancer case-control studies (approximately 12,000

101 Breast cancer case-control studies are being used to loo

102 as controls in one of two population-based, breast cancer case-control studies conducted in Los Ange

103 By evaluation of these SNPs in five breast cancer case-control studies involving more than 2

104 We analyzed data from a breast cancer case-control study (105 patients, 266 cont

105 ic association studies in a population-based breast cancer case-control study analysing polymorphisms

106 We applied the new assay to a breast cancer case-control study and identified the +/+

107 However, an Australian breast cancer case-control study found no association wi

108 bility (average Rh2=0.92) and genotyped in a breast cancer case-control study in the MEC (cases, n=13

109 erage R(h)(2) = 0.94) and were examined in a breast cancer case-control study in the Multiethnic Coho

110 mon BRCA2 haplotypes and were genotyped in a breast cancer case-control study nested in the MEC (case

111 ed for African Americans) and genotyped in a breast cancer case-control study nested in the Multiethn

112 y of 600 middle-aged men and women, and in a breast cancer case-control study, comprised 4647 cases a

113 ion with breast cancer risk in a Mayo Clinic breast cancer case-control study.

114 he Nurses' Health Study, with 1,506 invasive breast cancer cases diagnosed after blood donation in 19

115 trol study in the Nurses' Heath Study of 726 breast cancer cases diagnosed between June 1, 1992, and

116 The study included 1,687 incident breast cancer cases diagnosed from 1989 to 2000 and 4,70

117 a retrospective case-only study of 8860 AYA breast cancer cases diagnosed from 1997 to 2006 using th

118 Breast cancer cases diagnosed in 1999-2004 were identifi

119 Breast cancer cases during a mean (SD) follow-up of 9.3

120 A population-based series of 54 male breast cancer cases from Southern California were analyz

121 geons with higher volumes and percentages of breast cancer cases had a higher likelihood of undergoin

122 an average of 7.6 y, 2879 incident invasive breast cancer cases had been ascertained, of whom 2509 h

123 As of 31 December 2005, 629 incident breast cancer cases had been diagnosed among the 34,028

124 Only 3 of the breast cancer cases had no immunohistochemical evidence

125 Breast cancer cases had significantly lower (mean +/- SD

126 Analyses included 1,343 incident breast cancer cases identified during follow-up from 199

127 The analyses were limited to breast cancer cases identified during the period 1985-19

128 nits are frequently overexpressed in primary breast cancer cases in a correlative manner.

129 ive life, the authors evaluated 906 incident breast cancer cases in a nationwide cohort of 56,042 fem

130 proximately one-third of all newly diagnosed breast cancer cases in the United States and constitutes

131 g adults [AYAs]) constitutes 5% to 6% of all breast cancer cases in the United States.

132 Overall, 15.0% (95% CI, 12.8%-17.4%) of breast cancer cases in this population may be attributab

133 spective analysis among 188,860 women (7,582 breast cancer cases) in the Nurses' Health Study (1988-2

134 We compared 168 breast-cancer cases incident by 2000 with four matched c

135 od 15 June 1990-15 June 2008, 5,956 incident breast cancer cases (including 5,245 invasive tumors) we

136 A total of 304 incident breast cancer cases (including 62 in situ carcinomas) an

137 We postulated that breast cancer cases might have a higher prevalence of lo

138 Breast cancer cases (n = 1,199) were identified through

139 alidated in an additional independent set of breast cancer cases (n = 10).

140 A small number of breast cancer cases (n = 2) limited the statistical powe

141 Primary breast cancer cases (n = 2,325) in the 4-Corners region

142 Breast cancer cases (N = 247) diagnosed between collecti

143 Breast cancer cases (N = 4,935) aged 50-79 years were id

144 Population-based Hispanic breast cancer cases (n = 492) enrolled in the Northern C

145 Subjects were incident breast cancer cases (N = 497) and a subcohort (N = 2,830

146 screening was performed for Northern Finnish breast cancer cases (n = 578-1565) and controls (n = 337

147 Breast cancer cases (n = 7,591) were matched 1:4 to cont

148 A total of 1520 incident breast cancer cases occurred in the at-risk cohort of 37

149 Through December 31, 1992, 879 incident breast cancer cases occurred in this cohort.

150 ohort from 1971 to 1993, 221 and 66 incident breast cancer cases occurred, respectively.

151 The studies included 7377 incident invasive breast cancer cases occurring among 351 825 women whose

152 randomly selected controls and 850 incident breast cancer cases of the first four ethnic groups who

153 s at breast MR imaging--were matched to each breast cancer case on the basis of age and date of MR im

154 dential histories of 1,508 participants with breast cancer (case participants) and 1,556 particpants

155 s considered rare, constituting only 2-4% of breast cancer cases, poor prognosis means that patients

156 We identified T1a,bN0M0 breast cancer cases registered in the SEER Program from

157 We reviewed T1a,bN0M0 breast cancer cases registered in the Surveillance, Epid

158 Between 5% and 10% of breast cancer cases result from an inherited predisposit

159 encing in a multiethnic panel of 95 advanced breast cancer cases revealed no common missense variant

160 s of test area under ROC Curve (AUC), on all breast cancer case studies.

161 d and evaluated the proposed methods on five breast cancer case studies.

162 For the breast cancer case study using the full training set, th

163 Using the reduced training set in the breast cancer case study, the cumulative precision of ou

164 arger effect sizes in this study of familial breast cancer cases than in previous population-based st

165 alth Study (1997-2008) including 718 Chinese breast cancer cases, the authors evaluated baseline diet

166 cs is believed to account for only 10-15% of breast cancer cases, the environment, including nutritio

167 lse-positive controls were compared with the breast cancer cases: The ORs for moderate or marked BPE

168 In human breast cancer cases, there was a strong inverse correlat

169 available microarray datasets comprising 674 breast cancer cases to systematically investigate how ex

170 erformed a retrospective cohort study of all breast cancer cases treated from January 1, 2000, to May

171 nd 2 play a role only in a small fraction of breast cancer cases, understanding the genetic risk of t

172 and BRCA2 in the lymphocytes of non-familial breast cancer cases versus controls (BRCA1: 0.353, P = 0

173 1.5-57.0); the median surgeon percentage of breast cancer cases was 4.5% (range, 0.4%-100.0%).

174 The median annual surgeon Medicare volume of breast cancer cases was 6.0 (range, 1.5-57.0); the media

175 erience after first relapse in 1,696 primary breast cancer cases was analyzed using Cox proportional

176 When the age at diagnosis of the breast cancer cases was examined by OCCR, cases associat

177 llow-up period of 7.1 years (1987-1995), 187 breast cancer cases were ascertained.

178 Incident invasive breast cancer cases were confirmed by medical record rev

179 e first blood collection and June 2010, 2188 breast cancer cases were diagnosed (579 cases were diagn

180 Between 1995 and 2008, 2482 invasive breast cancer cases were diagnosed among 57,403 postmeno

181 A total of 2,416 breast cancer cases were diagnosed during follow-up (mea

182 ow-up (513,015 person-years), 1,459 invasive breast cancer cases were diagnosed.

183 During follow-up, a total of 5,483 invasive breast cancer cases were diagnosed.

184 low-up through June 30, 2007, 4,084 invasive breast cancer cases were diagnosed.

185 average of 7.35 y of follow-up, 616 incident breast cancer cases were documented.

186 Incident breast cancer cases were identified through linkage with

187 Incident breast cancer cases were identified through the New Jers

188 Through 2000, 309 incident breast cancer cases were identified via population-based

189 Breast cancer cases were identified via the Finnish Canc

190 During an average of 7 y of follow-up, 5461 breast cancer cases were identified, of which 3341 cases

191 ollow-up (2004 to 2011), 2,407 first primary breast cancer cases were identified.

192 hrough June 1, 1994, 1,761 incident invasive breast cancer cases were identified.

193 ng an average of 7 years of follow-up, 5,461 breast cancer cases were identified.

194 r and Nutrition cohort, 1502 female incident breast cancer cases were included, with an oversampling

195 Retrospective analysis of 372 breast cancer cases with assessable immunohistochemical

196 women between 1993-1996 and 2004/2005, 2,543 breast cancer cases with data on ER/PR status were ident

197 pes in 164 Caucasian and 59 African-American breast cancer cases with those in age-, race-, and frequ